Synlogic

Synlogic, Inc. engages in the discovery and development of synthetic biotic medicines. It focuses on phenylketonuria, enteric hyperoxaluria, immuno-oncology solid tumors, inflammatory bowel disease, and vaccines and other inflammatory programs. The company was founded by James J. Collins and Timothy K. Lu on August 28, 2017, and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Synlogic, Inc. is a biopharmaceutical company which engages in the discovery and development of synthetic biotic medicines. It focuses on phenylketonuria, enteric hyperoxaluria, immuno-oncology solid tumors, inflammatory bowel disease, and vaccines and other inflammatory programs. The company was founded by James J. Collins and Timothy K. Lu on December 20, 2007 and is headquartered in Cambridge, MA.

Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of -8.70% and 93.71%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Synlogic, Inc. (SYBX) Reports Q3 Loss, Tops Revenue Estimates

Top-line Phase 2 data for phenylketonuria (PKU) demonstrated robust plasma Phe reduction and high response rate; Phase 3 study initiation planned for H1 2023

Synlogic Reports Third Quarter 2022 Financial Results and Provides Business Update

Positive results include clinically meaningful Phe reductions, with a 60% response rate and 42% reduction in plasma Phe among responders across the study population

Synlogic Announces Positive Top-Line Phase 2 Data for Phenylketonuria (PKU); SYNB1934 Advances to Phase 3

CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, announced today that it has received a milestone payment for the achievement of prespecified success criteria under the research collaboration agreement with Roche for the discovery of a novel Synthetic Biotic for the treatment of inflammatory bowel disease (IBD).

Synlogic Achieves Research Milestone in Collaboration with Roche for Development of Novel Synthetic Biotic to Treat Inflammatory Bowel Disease

CAMBRIDGE, Mass., Aug. 23, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to SYNB1353 for the potential treatment of homocystinuria (HCU).

Synlogic Granted FDA Fast Track Designation for SYNB1353 for the Treatment of Homocystinuria (HCU)

Synlogic, Inc. (NASDAQ:SYBX ) Q2 2022 Earnings Conference Call August 11, 2022 8:30 AM ET Company Participants Andrew Funderburk - Kendall IR Aoife Brennan - CEO, President Michael Jensen - CFO Tony Awad - COO Molly Harper - Chief Business Officer Dave Hava - Chief Scientific Officer Conference Call Participants Joseph Schwartz - SVB Securities Mark Breidenbach - Oppenheimer Mitchell Kapoor - H.C. Wainwright Operator Good morning.

Synlogic, Inc. (SYBX) CEO Aoife Brennan on Q2 2022 Results - Earnings Call Transcript

Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of 4.35% and 49.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Synlogic, Inc. (SYBX) Reports Q2 Loss, Lags Revenue Estimates

Ginkgo Bioworks Holdings

SYNB2081 is the second clinical drug candidate developed through the partnership between Ginkgo and Synlogic CAMBRIDGE, Mass. and BOSTON , Aug. 11, 2022 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today announced a new drug candidate for the treatment of gout developed in partnership with Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming.

Synlogic Announces Synthetic Biotic for Gout Developed in Partnership with Ginkgo Bioworks

– Three clinical data readouts across three programs expected in H2 2022 –

Synlogic Reports Second Quarter 2022 Financial Results and Provides Business Update

Expected data in H2 2022 brings Synlogic to three clinical readouts this year

Synlogic Initiates Phase 1 Study of SYNB1353 for the Treatment of Homocystinuria (HCU)

CAMBRIDGE, Mass., June 29, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today announced the appointment of Brendan St. Amant as General Counsel and Corporate Secretary effective July 1, 2022.

Synlogic Announces Appointment of General Counsel and Corporate Secretary

VANCOUVER, Wash., June 28, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, announced today it will participate at the National PKU Alliance's (NPKUA) biennial conference July 7-10, 2022 in Vancouver, Washington. As an event sponsor, Synlogic has been invited to present during the session “What's New in PKU? (Emerging Therapies, Research, Foods & Beyond).” In addition, the team will share data on dietary protein intake in PKU patients during a poster presentation.

Synlogic to Present at the 2022 National PKU Alliance (NPKUA) Conference

BETHESDA, Md., June 21, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, announced it will participate in the HCU Network America, Organic Acidemia Association and Propionic Acidemia Foundation 2022 Conference, in Bethesda, Maryland, June 25-26, 2022. Synlogic has been invited to present a poster to patients and families affected by homocystinuria (HCU) regarding SYNB1353, an investigational oral therapy designed to consume methionine for the potential treatment of HCU.

Synlogic to Present at the 2022 HCU Network America, Organic Acidemia Association and Propionic Acidemia Foundation Conference

Synlogic, Inc. (NASDAQ:SYBX ) Q1 2022 Earnings Conference Call May 12, 2022 8:30 AM ET Company Participants Andrew Funderburk - Kendall Investor Relations Aoife Brennan - Chief Executive Officer, President Molly Harper - Chief Business Officer Dave Hava - Chief Scientific Officer Michael Jensen - Chief Financial Officer Tony Awad - Chief Operating Officer Conference Call Participants Keay Nakae - Chardan Mark Breidenbach - Oppenheimer Operator Good morning, and welcome to Synlogic's First Quarter 2022 Conference Call. At this time all participants are in a listen-only mode.

Synlogic, Inc. (SYBX) CEO Aoife Brennan on Q1 2022 Results - Earnings Call Transcript

Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of 4.35% and 51.20%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Synlogic, Inc. (SYBX) Reports Q1 Loss, Misses Revenue Estimates

- Clinical readouts anticipated for phenylketonuria (PKU), homocystinuria (HCU) and enteric hyperoxaluria programs in H2 2022 –

Synlogic Reports First Quarter 2022 Financial Results and Provides Business Update

CAMBRIDGE, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today announced its planned presentations at the 2022 Synthetic Biology: Engineering, Evolution & Design (SEED) conference being held May 2-5, 2022, in Arlington, VA. The oral presentation outlines Synlogic's progress in developing Synthetic Biotic drug candidates for rare metabolic diseases phenylketonuria (PKU) and homocystinuria (HCU), both inborn errors of metabolism. The poster presentations highlight preclinical and clinical data across five different Synlogic programs. Presentation details are provided below.

Synlogic Announces Data Presentations from Five Programs at the 2022 Synthetic Biology: Engineering, Evolution & Design (SEED) Conference

CAMBRIDGE, Mass., April 01, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today announced that data from its phenylketonuria (PKU) and homocystinuria (HCU) programs will be highlighted in two poster presentations at the Society for Inherited Metabolic Disorders (SIMD) 43rd Annual Meeting being held April 10-13, 2022 in Orlando, Florida.

Synlogic to Present Data on Phenylketonuria and Homocystinuria Programs at the Society for Inherited Metabolic Disorders 43rd Annual Meeting

Synlogic, Inc. (SYBX) CEO Aoife Brennan on Q4 2021 Results - Earnings Call Transcript

- Phenylketonuria (PKU) program on track for Phase 3 trial initiation in H2 2022 –

Synlogic Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

CAMBRIDGE, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today announced the Company will release its fourth quarter and full year 2021 financial results before the market opens on Thursday, March 17, 2022. The press release will be followed by a conference call at 8:30 am ET, which will be open to the public via telephone and webcast. During the conference call, the Company will review its financial results and provide a corporate update.

Synlogic Announces Fourth Quarter and Full Year 2021 Conference Call and Webcast

CAMBRIDGE, Mass., March 03, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today announced the appointment of Michael Jensen as Chief Financial Officer. Mr. Jensen brings extensive and diversified experience within global pharmaceutical and medical device companies to Synlogic, spanning analytics, financial management, information systems, and operations.

Synlogic Announces Appointment of Michael Jensen as Chief Financial Officer

Synlogic, Inc. (SYBX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

What Makes Synlogic, Inc. (SYBX) a New Buy Stock

CAMBRIDGE, Mass., Nov. 22, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage company bringing the transformative potential of synthetic biology to medicine, today announced presentation of interim data from the company's Phase 2 SynPheny-1 clinical trial showing that treatment with the investigational Synthetic BioticTM medicine SYNB1618 resulted in significant reductions in plasma phenylalanine (Phe) levels in patients with phenylketonuria (PKU).

Synlogic Presents Data Demonstrating Reductions in Plasma Phenylalanine Levels in Patients with Phenylketonuria Treated with SYNB1618

Synlogic, Inc. (SYBX) CEO Aoife Brennan on Q3 2021 Results - Earnings Call Transcript

News for Synlogic Stock (SYBX)